LATEST NEWS
Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics
27 . 02 . 26
Boehringer has acquired an exclusive license for a preclinical, small molecule program from Sitryx, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases, based...
Read More